

Date: May 18, 2024 Ref. No.: KDL/SE/21/2024-25

То,	То,
BSE Limited	National Stock Exchange of India Limited
Corporate Relationship Department	Exchange Plaza, Plot No. C-1, Block G,
25th Floor, Phiroze Jeejeebhoy Towers	Bandra Kurla Complex, Bandra (East)
Dalal Street, Mumbai- 400001	Mumbai – 400051
Scrip Code: 543328	NSE Symbol: KRSNAA

Dear Sir/Madam,

Sub: Statement on Deviation or Variation of funds under Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Statement on Deviation/Variation in the utilization of proceeds for objects as stated in the prospectus dated August 10, 2021, of Initial Public Offer (IPO), for the quarter ended March 31, 2024.

Further, the Company wishes to inform that the utilization of funds raised through the IPO has been completely utilized for the objects as mentioned in the Prospectus dated August 10, 2021.

(RS)

Kindly take this on your records.

For Krsnaa Diagnostics Limited



Sujoy Sudipta Bose Company Secretary & Compliance Officer Encl: As above

Krsnaa Diagnostics Ltd.

S.No. 243/A, Hissa No. 6, CTS No. 4519, 4519/1, Near Chinchwad Station, Chinchwad, Taluka - Haveli, Pune, MH - 411019 (India) 020 27402400 | info@krsnaa.in

	Krsnaa Diagnostics Limited	1				
Aode of Fund Raising	Public Issues / Rights Issues /	1				
	Preferential Issues					
	/ QI P / Others					
ate of Raising Funds	16-Aug-21	1				
mount Raised	400 Crores	1				
eport filed for Quarter ended	31-Mar-24	1				
Ionitoring Agency	applicable / not applicable	1				
Ionitoring Agency Name, if applicable	ICICI Bank Limited	1				
there a Deviation / Variation in use of funds raised	Yes / No	1				
yes, whether the same is pursuant to change in terms of a contract		1				
r objects, which was approved	-					
y the shareholders		I.				
Yes, Date of shareholder Approval	-]				
xplanation for the Deviation / Variation	-	1				
omments of the Audit Committee after review	The Audit Committee reviewed the	1				
	Statement of Deviation/Variation for					
	the utilization of funds raised through					
	the IPO for the quarter ended March					
	31, 2024, as placed before its meeting					
	held on May 18, 2024 and noted that					
	the complete utilization of the said					
	funds.					
omments of the auditors, if any		l				
bjects for which funds have been raised and where		1				
ere has been a deviation, in the following table	-					
Original Object	Modified Object, if any	Original Allocation	Modified allocation, if any	Funds Utilised	Amount of Deviation/Variation f ^o r the quarter according to applicable object	Remarks if any
NIL	NIL	NIL	NIL		NIL	

(b) Deviation in the amount of funds actually utilized as against what was originally disclosed or

Sawar

(c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc

Name of Signatory: Mr. Pawan Daga

Designation: Chief Financial Officer

Oiagnostic, rsnag Limite